These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3477461)

  • 21. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year.
    Low RN; Duggan B; Barone RM; Saleh F; Song SY
    Radiology; 2005 Jun; 235(3):918-26. PubMed ID: 15914479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
    García Enguídanos A; Crespo Azanza E; Díaz Recaséns J; Lobo Samper F; Jorge Herrero JA; Sáinz de la Cuesta Abbad R
    Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
    Lahousen M
    Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
    Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
    Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Second-look laparotomy in epithelial ovarian cancer: an evaluation of 23 cases].
    Liu LY
    Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):77-9, 123. PubMed ID: 2364794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
    Sevelda P; Salzer H; Dittrich C; Spona J
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation.
    Mogensen O; Mogensen B; Jakobsen A; Sell A
    Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1835-7. PubMed ID: 3220081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second look laparotomy in the management of malignant epithelial ovarian neoplasias.
    Facchini V; Gadducci A; Del Bravo B; Colombi L; Bartolini T; Manfredini C; Fioretti P
    Eur J Gynaecol Oncol; 1986; 7(2):122-9. PubMed ID: 3459658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer.
    Sugiyama T; Nishida T; Komai K; Nishimura H; Yakushiji M; Nishimura H
    Int J Gynaecol Obstet; 1996 Sep; 54(3):251-6. PubMed ID: 8889633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
    J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of second-look laparotomy for ovarian cancer: second-look vs. serum CA125.
    Liu L; Hong W; Hou Y; Yao Z; Wu A; Wang X
    Chin Med Sci J; 1991 Jun; 6(2):96-9. PubMed ID: 1804384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CA125 as a serum marker for poor prognosis in ovarian malignancies.
    Alvarez RD; To A; Boots LR; Shingleton HM; Hatch KD; Hubbard J; Soong SJ; Potter ME
    Gynecol Oncol; 1987 Mar; 26(3):284-9. PubMed ID: 2435619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of serum CA-125 and lipid-associated sialic acid (LASA-P) in monitoring patients with invasive ovarian adenocarcinoma.
    Patsner B; Mann WJ; Vissicchio M; Loesch M
    Gynecol Oncol; 1988 May; 30(1):98-103. PubMed ID: 2452774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U; Johannsen B; Elling D
    Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination--a longitudinal study.
    Low RN; Saleh F; Song SY; Shiftan TA; Barone RM; Lacey CG; Goldfarb PM
    Radiology; 1999 May; 211(2):519-28. PubMed ID: 10228537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
    Göcze P; Vahrson H
    Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients.
    Hising C; Anjegård IM; Einhorn N
    Am J Clin Oncol; 1991 Apr; 14(2):111-4. PubMed ID: 2028919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival.
    Friedman RL; Eisenkop SM; Wang HJ
    Gynecol Oncol; 1997 Oct; 67(1):88-94. PubMed ID: 9345362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrasound examination in ovarian cancer patients. A comparison with second look laparotomy.
    Murolo C; Costantini S; Foglia G; Guido T; Odicino F; Pace M; Parodi S; Pino G; Ragni N; Repetto L
    J Ultrasound Med; 1989 Aug; 8(8):441-3. PubMed ID: 2668555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer.
    Prayer L; Kainz C; Kramer J; Stiglbauer R; Schurawitzki H; Baldt M; Schima W; Poelzleitner D; Reinthaller A; Koelbl H
    J Comput Assist Tomogr; 1993; 17(4):626-32. PubMed ID: 8331235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.